Catalyst
Slingshot members are tracking this event:
Heron (HRTX) Expects FDA Decision on November 12th, 2017 for Cinvanti (HTX-019) in Treatment of Chemotherapy-Induced Nausea & Vomiting (CINV)
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| HRTX |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 09, 2017
Occurred Source:
http://phx.corporate-ir.net/phoenix.zhtml?c=115565&p=irol-newsArticle&ID=2316008
Related Projects
- Taking an informed look at Cinvanti IV, Heron’s complementary drug to Sustol in Chemotherapy-Induced Nausea & Vomiting after Nov 9th approval HRTX, MRK Executed On: Nov 22, 2017 at 11:30 AM EST
Related Keywords
Fda Decision, Cinvanti, Htx-019, Chemotherapy-induced Nausea And Vomiting, Cinv
